Literature DB >> 24163726

Serotonin uptake rates in platelets from angiotensin II-induced hypertensive mice.

Preeti Singh1, Terry W Fletcher, Yicong Li, Nancy J Rusch, Fusun Kilic.   

Abstract

Angiotensin II (Ang II) is a critical component of the renin-angiotensin system that contributes to hypertension. Although platelets in blood from hypertensive subjects have an abnormal biological profile, it is unclear if circulating Ang II influences platelet aggregation or thrombus formation. One of the abnormalities presented to the platelets during hypertension is an elevated plasma concentration of serotonin (5-HT) caused by reduced 5-HT uptake secondary to loss of the 5-HT transporter (SERT) on the platelet plasma membrane. In the current study, we evaluated in vivo platelet function after 7 days of subcutaneous Ang II infusion to establish hypertension in mice and additionally assessed the biology of isolated platelets exposed to Ang II in vitro. The administration of Ang II elevated systolic blood pressure, but markers of platelet activation including P-selectin and PEJon/A staining were not changed. However, the aggregation response to collagen was reduced in isolated platelets from Ang II-infused mice, which also showed reduced 5-HT uptake by SERT. In vitro exposure of isolated platelets to Ang II also resulted in a loss of surface SERT associated with a reduced aggregation response to collagen. These abnormalities were reversed by increasing concentrations of the Ang II receptor antagonist, valsartan. Interestingly, SERT KO mice failed to fully develop hypertension in response to Ang II infusion and isolated platelets from these animals were insensitive to the anti-aggregatory influence of Ang II. Thus, Ang II blunts the aggregation responses of platelets and the mechanism underlying this action may involve a loss of SERT on the platelet plasma membrane. The latter event depletes intracellular 5-HT in platelets, an event that is associated with reduced aggregation. The widespread use of antihypertensive drugs that target the renin-angiotensin system suggest the potential clinical utility of our findings and emphasize the importance of understanding the impact of Ang II on platelet function.

Entities:  

Keywords:  Angiotensin; Hypertension; Platelet; Serotonin

Year:  2013        PMID: 24163726      PMCID: PMC3806217          DOI: 10.4236/health.2013.54A005

Source DB:  PubMed          Journal:  Health (Irvine Calif)        ISSN: 1949-4998


  38 in total

1.  Characterization of monoclonal antibodies against mouse and rat platelet glycoprotein V (CD42d).

Authors:  N Sato; N Kiyokawa; K Takada; M Itagaki; M Saito; T Sekino; T Suzuki; T Taguchi; K Mimori; F Lanza; J Fujimoto
Journal:  Hybridoma       Date:  2000-12

2.  Nitric oxide released from activated platelets inhibits platelet recruitment.

Authors:  J E Freedman; J Loscalzo; M R Barnard; C Alpert; J F Keaney; A D Michelson
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

3.  Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites.

Authors:  M M Muthalif; N A Karzoun; L Gaber; Z Khandekar; I F Benter; A E Saeed; J H Parmentier; A Estes; K U Malik
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

4.  Determinants of platelet activation in human essential hypertension.

Authors:  Pietro Minuz; Paola Patrignani; Stefania Gaino; Francesca Seta; Marta L Capone; Stefania Tacconelli; Maurizio Degan; Giovanni Faccini; Anna Fornasiero; Giorgio Talamini; Rosamaria Tommasoli; Enrico Arosio; Clara Lechi Santonastaso; Alessandro Lechi; Carlo Patrono
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 5.  The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation.

Authors:  Sheila A Doggrell
Journal:  Expert Opin Investig Drugs       Date:  2003-05       Impact factor: 6.206

Review 6.  Platelet-derived nitric oxide signaling and regulation.

Authors:  Eugenia Gkaliagkousi; James Ritter; Albert Ferro
Journal:  Circ Res       Date:  2007-09-28       Impact factor: 17.367

7.  Serotonin transamidates Rab4 and facilitates its binding to the C terminus of serotonin transporter.

Authors:  Billow A Ahmed; Brandon C Jeffus; Syed I A Bukhari; Justin T Harney; Resat Unal; Vladimir V Lupashin; Peter van der Sluijs; Fusun Kilic
Journal:  J Biol Chem       Date:  2008-01-28       Impact factor: 5.157

8.  Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans.

Authors:  Ana Marin D Carneiro; Edwin H Cook; Dennis L Murphy; Randy D Blakely
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release.

Authors:  Diego J Walther; Jens-Uwe Peter; Sandra Winter; Markus Höltje; Nils Paulmann; Maik Grohmann; Jakob Vowinckel; Victor Alamo-Bethencourt; Claudia S Wilhelm; Gudrun Ahnert-Hilger; Michael Bader
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

10.  Plasma serotonin levels and the platelet serotonin transporter.

Authors:  B Brenner; J T Harney; B A Ahmed; B C Jeffus; R Unal; J L Mehta; F Kilic
Journal:  J Neurochem       Date:  2007-05-15       Impact factor: 5.372

View more
  4 in total

Review 1.  Serotonin: a different player in hypertension-associated thrombosis.

Authors:  Mony Fraer; Fusun Kilic
Journal:  Hypertension       Date:  2015-03-09       Impact factor: 10.190

2.  Loss of Serotonin Transporter Function Alters ADP-mediated Glycoprotein αIIbβ3 Activation through Dysregulation of the 5-HT2A Receptor.

Authors:  Kendra H Oliver; Matthew T Duvernay; Heidi E Hamm; Ana M D Carneiro
Journal:  J Biol Chem       Date:  2016-07-15       Impact factor: 5.157

3.  Serotonin: an overlooked regulator of endocytosis and endosomal sorting?

Authors:  Gregory Redpath; Nikita Deo
Journal:  Biol Open       Date:  2022-01-25       Impact factor: 2.422

4.  Telotristat ethyl reverses myxomatous changes in mice mitral valves.

Authors:  Xinmei Wang; Danielle Kuban-Johnston; Pablo Lapuerta; Carla M R Lacerda
Journal:  Front Cardiovasc Med       Date:  2022-08-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.